for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sa Sa International Holdings Limited

0178.HK

Latest Trade

1.86HKD

Change

-0.02(-1.06%)

Volume

2,620,000

Today's Range

1.84

 - 

1.89

52 Week Range

1.06

 - 

2.29

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.88
Open
1.88
Volume
2,620,000
3M AVG Volume
225.68
Today's High
1.89
Today's Low
1.84
52 Week High
2.29
52 Week Low
1.06
Shares Out (MIL)
3,103.19
Market Cap (MIL)
5,834.00
Forward P/E
63.52
Dividend (Yield %)
--

Next Event

Sa Sa International Holdings Ltd Annual Shareholders Meeting

Latest Developments

更多

Sa Sa International FY Loss Attributable HK$351.4 Mln

SA SA International Sees FY Loss Of About HK$300 Million To HK$340 Million From Cont Ops

SA SA International Holdings Q3 Retail And Wholesale Turnover HK$938.1 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sa Sa International Holdings Limited

Sa Sa International Holdings Ltd is an investment holding company principally engaged in the beauty products retailing business in Asia. The Company sells skincare, fragrance, make-up, hair care and body care products, as well as health and beauty supplements through its own brands and exclusive international brands. It operates retail stores in Hong Kong and Macau Special Administrative Region, Mainland China and Malaysia. The Company also provides online shopping services through e-commerce platforms.

Industry

Retail (Specialty)

Contact Info

14F, Block B, MP Industrial Centre

18 Ka Yip Street, Chai Wan

Hong Kong

+852.null.28892331

http://www.sasa.com/

Executive Leadership

Siu Ming Kwok

Executive Chairman of the Board, Chief Executive Officer

Kwai Chun Kwok Law

Executive Vice Chairman of the Board

Guy Look

Chief Financial Officer, Executive Director

Sum Wun Mak

Senior Vice President, General Counsel, Company Secretary

Kin Ming Law

Senior Vice President - Category Management & Product Development

Key Stats

3.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2019

8.4K

2020

5.7K

2021

3.0K

2022(E)

4.6K
EPS (HKD)

2019

0.154

2020

-0.167

2021

-0.113

2022(E)

0.031
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.92
Price To Book (MRQ)
4.39
Price To Cash Flow (TTM)
37.44
Total Debt To Equity (MRQ)
48.80
LT Debt To Equity (MRQ)
22.52
Return on Investment (TTM)
-18.60
Return on Equity (TTM)
-12.44

Latest News

Latest News

MIDEAST STOCKS-Qatar bourse gains as major Gulf markets ease

Most major stock markets in the Gulf ended lower on Wednesday, extending losses from the previous session, after Saudi Arabia amended import rules from the Gulf in a challenge to the United Arab Emirates, although Qatar bucked the trend. Saudi Arabia's benchmark index fell...

莎莎国际2020/21年度净亏损收窄,新财年首季营业额暂录55%升幅

在新冠病毒疫情打击消费市道下,化妆品零售商--莎莎国际周三公布的2020/21年度业绩继续录得净亏损,但较前一年度则有所收窄;随着疫情趋缓,自今年4月1日至6月9日的首季度,公司的零售及批发营业额则录得55.1%的按年升幅。

综述:香港新冠疫情恶化本地感染数急增 社区大爆发学校提早放暑假

香港新冠病毒疫情突然急速恶化,且有不少个案找不到源头,情况令人担忧;鉴于社区大爆发,政府周五宣布全港中小学及幼稚园下周提早放暑假,为本周以来第三度出招。

分析:新冠病毒殃经济 恐给香港盛极一时的旅游和零售业致命一击

去年香港历经数月之久的大规模抗议活动,酒店和餐厅门可罗雀,Tom Bennell的橄榄油配销业务因此遭受重创,如今香港又得力抗新冠病毒疫情,Bennell担心他的事业恐遭致命打击。

莎莎国际港澳21家分店暂停营业 因应新型肺炎蔓延及消费转弱

香港连锁化妆品零售商--莎莎国际<0178.HK>周一宣布,因应目前新型冠状病毒肺炎蔓延情况,为保障员工及顾客安全,并考虑到顾客消费需求减低,旗下香港及澳门共21家分店已暂停或将暂停营业。

肺炎疫情:香港零售业步入超级寒冬,料2-3月生意额跌幅高至60%--调查

香港零售管理协会周四公布其最新调查显示,自1月24日起共10天的春节期间,大部分本港零售商的平均生意额下跌高至50%,零售业正步入“超级寒冬”;而在新型冠状病毒疫情肆虐下,协会会员预计2-3月的生意额仍会下跌40-60%,倘业界未能得到及时适切支援,可能会出现大型结业潮。

莎莎国际春节期间港澳零售销售暴跌77% 受新型冠状病毒疫情拖累

受新型冠状病毒事件影响拖累,香港连锁化妆品零售商--莎莎国际<0178.HK>周四称,于1月25日至31日新春期间,香港及澳门零售销售同比大跌76.9%。公司并表示,全体执行董事将减薪75%三个月,作为新一轮降低成本方案的第一步。

香港经济:去年下半年访港旅客大减四成,莎莎开始缩减游客区店舖

由于社会动荡持续升级,香港于2019年下半年访港旅客按年大减四成,并拖累本地消费表现,香港大型化妆品零售商莎莎周三宣布开始缩减游客区为主的店舖,同时积极与业主磋商租金。

香港个股:莎莎国际发盈警,受本地示威活动及人民币贬值等拖累

香港连锁化妆品零售商--莎莎国际周三发出盈利预警,因核心市场香港地区持续不断的社会活动及其他因素影响,导致访港内地旅客锐减并打击销售,公司截至8月底本财政年度首五个月业绩将录得亏损。

港报社评:港府尽速息风波,免挫损经济--经济日报7月17日

连串反对修订《逃犯条例》的示威游行,影响零售生意,暴力冲突场面亦吓怕了游客,令本已疲弱的零售业雪上加霜。为免事态进一步恶化,损害经济,港府须尽快设法平息风波。

《香港报摘》--其他报纸重要消息9月17日

--华领医药执行副总裁兼首席财务官林洁诚表示,公司将于1年后公布药物第三期临牀试验数据,通常公司公布亮丽数据后,股价可马上飈升4至5倍,所以如果延后上市计划,投资者就会质疑为什么不待数据出炉后才上市,届时就影响之后试验及准备商品商业化的进度。

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up